Now Live: Phoenix Pharma Labs

Click to rate this post!
[Total: 0 Your Rating: 0]

Now Live: Phoenix Pharma Labs
$160K+ raised | $99 min. investment | 205 investors

The market for opioids is estimated to reach $34.96 billion by 2025 and is growing at a rate of about 5% per year…

The CDC has declared that โ€œaddiction to prescription opioids is a major public health problem that is getting worse and getting worse rapidly.โ€ The opioid epidemic is killing almost 50,000 Americans a year and costs the U.S. economy $696 billion a year, according to the Council of Economic Advisers (CEA).

Phoenix PharmaLabs (PPL) is a preclinical drug discovery company dedicated to the development of potent, safe, non-addictive treatments for pain and addiction. PPLโ€™s lead drug, PPL-103, has demonstrated in animal studies that it is a very potent painkiller (10x more potent than morphine), and is non-addictive, does not produce withdrawal, does not cause death from overdose at elevated doses, and causes no constipation.
Deal Highlights
PPL-103 has also demonstrated effectiveness in treating opioid and cocaine addictions.
The company was awarded a $2.7 million grant from the US Army Medical Research and Material Command and a $185,000 grant from the NIH / NIDA (National Institute for Drug Abuse
Phoenix closed its first Netcapital round in March 2019, which was oversubscribed at $1.1M
Currently in the process of applying for new grants to support the advancement of PPL-138 into human clinical trial


Join Our Newsletter



By Registering, you agree that you've read and accepted our disclaimer, you're at least 18 years old, you consent to the terms presented on the disclaimer, and to receive notifications from us.